What is Clinuvel Pharmaceuticals Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Clinuvel Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was $14.64 Mil. Clinuvel Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $114.91 Mil. Therefore, Clinuvel Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 12.74%.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
CLVLF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -78.2 Med: 23.32 Max: 40.93
Current: 18.77
During the past 13 years, Clinuvel Pharmaceuticals's highest Return-on-Tangible-Equity was 40.93%. The lowest was -78.20%. And the median was 23.32%.
CLVLF's Return-on-Tangible-Equity is ranked better than 92.53% of 1312
companies
in the Biotechnology industry
Industry Median: -47.715
vs CLVLF: 18.77
Clinuvel Pharmaceuticals Return-on-Tangible-Equity Historical Data
The historical data trend for Clinuvel Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clinuvel Pharmaceuticals's Return-on-Tangible-Equity
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals's Return-on-Tangible-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2023) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Clinuvel Pharmaceuticals Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLVLF has been successfully added to your 